These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

332 related articles for article (PubMed ID: 25039448)

  • 1. Higher insulin detemir doses are required for the similar glycemic control: comparison of insulin detemir and glargine in children with type 1 diabetes mellitus.
    Abalı S; Turan S; Atay Z; Güran T; Haliloğlu B; Bereket A
    Pediatr Diabetes; 2015 Aug; 16(5):361-6. PubMed ID: 25039448
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of insulin detemir and insulin glargine in a basal-bolus regimen, with insulin aspart as the mealtime insulin, in patients with type 1 diabetes: a 52-week, multinational, randomized, open-label, parallel-group, treat-to-target noninferiority trial.
    Heller S; Koenen C; Bode B
    Clin Ther; 2009 Oct; 31(10):2086-97. PubMed ID: 19922879
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Switching from twice-daily glargine or detemir to once-daily degludec improves glucose control in type 1 diabetes. An observational study.
    Galasso S; Facchinetti A; Bonora BM; Mariano V; Boscari F; Cipponeri E; Maran A; Avogaro A; Fadini GP; Bruttomesso D
    Nutr Metab Cardiovasc Dis; 2016 Dec; 26(12):1112-1119. PubMed ID: 27618501
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Glycemic Control in Adult Type 1 Diabetes Patients with Insulin Glargine, Insulin Detemir, or Continuous Subcutaneous Insulin Infusion in Daily Practice.
    Rautiainen P; Tirkkonen H; Laatikainen T
    Diabetes Technol Ther; 2018 May; 20(5):363-369. PubMed ID: 29741925
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A 52-week, multinational, open-label, parallel-group, noninferiority, treat-to-target trial comparing insulin detemir with insulin glargine in a basal-bolus regimen with mealtime insulin aspart in patients with type 2 diabetes.
    Hollander P; Cooper J; Bregnhøj J; Pedersen CB
    Clin Ther; 2008 Nov; 30(11):1976-87. PubMed ID: 19108786
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Deleterious outcomes after abrupt transition from insulin glargine to insulin detemir in patients with type 1 diabetes mellitus.
    Kabadi UM
    Clin Drug Investig; 2008; 28(11):697-701. PubMed ID: 18840012
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A crossover comparison of glycemic variations in Japanese patients with type 1 diabetes receiving insulin glargine versus insulin detemir twice daily using continuous glucose monitoring (CGM): J COLLECTION (Jikei COmparison of Lantus and LEvemir with Cgm for Thinking Insulin OptimizatioN).
    Tsujino D; Nishimura R; Morimoto A; Tajima N; Utsunomiya K
    Diabetes Technol Ther; 2012 Jul; 14(7):596-601. PubMed ID: 22775404
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Non-inferiority of insulin glargine versus insulin detemir on blood glucose variability in type 1 diabetes patients: a multicenter, randomized, crossover study.
    Renard E; Dubois-Laforgue D; Guerci B;
    Diabetes Technol Ther; 2011 Dec; 13(12):1213-8. PubMed ID: 21810024
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Changing basal insulin from NPH to detemir or glargine in patients with type 1 diabetes and a history of severe hypoglycemia.
    Johansen OE; Vanberg PJ; Kilhovd BK; Jørgensen AP
    Vasc Health Risk Manag; 2009; 5(1):121-8. PubMed ID: 19436668
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of the efficacy and safety of insulin glargine and insulin detemir with NPH insulin in children and adolescents with type 1 diabetes mellitus receiving intensive insulin therapy.
    Dündar BN; Dündar N; Eren E
    J Clin Res Pediatr Endocrinol; 2009; 1(4):181-7. PubMed ID: 21274293
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adjustment of insulin doses when switching from glargine 100 U/ml or detemir to degludec: an observational study.
    Lualdi C; Silverii A; Dicembrini I; Pala L; Monami M; Mannucci E
    J Endocrinol Invest; 2019 Mar; 42(3):319-326. PubMed ID: 29987755
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Metabolic control by insulin detemir in basal-bolus therapy: treat-to-target study in children and adolescents with type 1 diabetes.
    Nimri R; Lebenthal Y; Shalitin S; Benzaquen H; Demol S; Phillip M
    Pediatr Diabetes; 2013 May; 14(3):196-202. PubMed ID: 23289822
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparing dosing of basal insulin analogues detemir and glargine: is it really unit-per-unit and dose-per-dose?
    Wallace JP; Wallace JL; McFarland MS
    Ann Pharmacother; 2014 Mar; 48(3):361-8. PubMed ID: 24396092
    [TBL] [Abstract][Full Text] [Related]  

  • 14. (Ultra-)long-acting insulin analogues for people with type 1 diabetes mellitus.
    Hemmingsen B; Metzendorf MI; Richter B
    Cochrane Database Syst Rev; 2021 Mar; 3(3):CD013498. PubMed ID: 33662147
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-acting Insulin Analogs Effect on gh/igf Axis of Children with Type 1 Diabetes: a Randomized, Open-label, Two-period, Cross-over Trial.
    Cherubini V; Pintaudi B; Iannilli A; Pambianchi M; Ferrito L; Nicolucci A
    Exp Clin Endocrinol Diabetes; 2016 May; 124(5):276-82. PubMed ID: 27023008
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Usefulness of insulin detemir in Japanese children with type 1 diabetes.
    Jinno K; Urakami T; Horikawa R; Kawamura T; Kikuchi N; Kikuchi T; Kizu R; Kosaka K; Mizuno H; Mochizuki T; Nishii A; Ohki Y; Soneda S; Sugihara S; Tatematsu T; Amemiya S;
    Pediatr Int; 2012 Dec; 54(6):773-9. PubMed ID: 22726205
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Outcomes of glycemic control in type 1 diabetic patients switched from basal insulin glargine 100 U/ml to glargine 300 U/ml in real life.
    Oriot P; Jérémie W; Buysschaert M
    Expert Rev Endocrinol Metab; 2018 May; 13(3):167-171. PubMed ID: 30058899
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Clinical experiences with basal analogue insulin in routine care. Retrospective follow up analysis of a database from daily routine care].
    Sudár Z; Muth L; Nyirati C; Szí V; Tornóczky J; Ulrich G
    Orv Hetil; 2013 Sep; 154(37):1476-84. PubMed ID: 24016754
    [TBL] [Abstract][Full Text] [Related]  

  • 19. COMPARISON OF EFFICACY AND SAFETY OF GLARGINE AND DETEMIR INSULIN IN THE MANAGEMENT OF INPATIENT HYPERGLYCEMIA AND DIABETES.
    Galindo RJ; Davis GM; Fayfman M; Reyes-Umpierrez D; Alfa D; Peng L; Tamler R; Pasquel FJ; Umpierrez GE
    Endocr Pract; 2017 Sep; 23(9):1059-1066. PubMed ID: 28683239
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Once-daily insulin detemir is comparable to once-daily insulin glargine in providing glycaemic control over 24 h in patients with type 2 diabetes: a double-blind, randomized, crossover study.
    King AB
    Diabetes Obes Metab; 2009 Jan; 11(1):69-71. PubMed ID: 19120433
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.